J Cancer
2018; 9(8):1329-1336.
doi:10.7150/jca.21915 This issueCite
Research Paper
Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway
Tian Liao*, Wen-Jun Wei*, Duo Wen*, Jia-Qian Hu, Yu Wang, Ben Ma, Yi-Min Cao, Jun Xiang, Qing Guan, Jia-Ying Chen, Guo-Hua Sun, Yong-Xue Zhu, Duan-Shu Li, Qing-Hai Ji✉
Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. * These authors have contributed equally to this work.
✉ Corresponding author: Qing-Hai JI, Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Phone: 0086-021-64175590, fax: 0086-021-64175590. E-mail: ji_qh2015comMore
Citation:
Liao T, Wei WJ, Wen D, Hu JQ, Wang Y, Ma B, Cao YM, Xiang J, Guan Q, Chen JY, Sun GH, Zhu YX, Li DS, Ji QH. Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway. J Cancer 2018; 9(8):1329-1336. doi:10.7150/jca.21915. https://www.jcancer.org/v09p1329.htm
Verteporfin, a FDA approved second-generation photosensitizer, has been demonstrated to have anticancer activity in various tumors, but not including papillary thyroid cancer (PTC). In current pre-clinical pilot study, we investigate the effect of verteporfin on proliferation, apoptosis, cell cycle and tumor growth of PTC. Our results indicate verteporfin attenuates cell proliferation, arrests cell cycle in G2/S phase and induces apoptosis of PTC cells. Moreover, treatment of verteporfin dramatically suppresses tumor growth from PTC cells in xenograft mouse model. We further illustrate that exposure to MEK inhibitor U0126 inactivates phosphorylation of ERK1/2 and MEK in verteporfin-treated PTC cells. These data suggest verteporfin exhibits inhibitory effect on PTC cells proliferation and cell cycle partially via ERK1/2 signalling pathway, which strongly encourages the further application of verteporfin in the treatment against PTC.
Liao, T., Wei, W.J., Wen, D., Hu, J.Q., Wang, Y., Ma, B., Cao, Y.M., Xiang, J., Guan, Q., Chen, J.Y., Sun, G.H., Zhu, Y.X., Li, D.S., Ji, Q.H. (2018). Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway. Journal of Cancer, 9(8), 1329-1336. https://doi.org/10.7150/jca.21915.
ACS
Liao, T.; Wei, W.J.; Wen, D.; Hu, J.Q.; Wang, Y.; Ma, B.; Cao, Y.M.; Xiang, J.; Guan, Q.; Chen, J.Y.; Sun, G.H.; Zhu, Y.X.; Li, D.S.; Ji, Q.H. Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway. J. Cancer 2018, 9 (8), 1329-1336. DOI: 10.7150/jca.21915.
NLM
Liao T, Wei WJ, Wen D, Hu JQ, Wang Y, Ma B, Cao YM, Xiang J, Guan Q, Chen JY, Sun GH, Zhu YX, Li DS, Ji QH. Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway. J Cancer 2018; 9(8):1329-1336. doi:10.7150/jca.21915. https://www.jcancer.org/v09p1329.htm
CSE
Liao T, Wei WJ, Wen D, Hu JQ, Wang Y, Ma B, Cao YM, Xiang J, Guan Q, Chen JY, Sun GH, Zhu YX, Li DS, Ji QH. 2018. Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway. J Cancer. 9(8):1329-1336.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Global reach, higher impact
